Home Tags Immunomedics

Tag: Immunomedics

United States Patent and Trademark Office Awards New Patents to Immunomedics

Earlier this month the United States Patent and Trademark Office awarded U.S. Patent 9,458,242 to Immunomedics for additional claims under the patent family “Dosages of...

Enhancing Activity of Sacituzumab Govitecan in SN-38-Resistant Cancer

Adding an inhibitor of ATP-binding cassette (ABC) transporters to sacituzumab govitecan increased the median survival of mice bearing a SN-38-resistant human gastric cancer cell...

New U.S. Patent and Updated Clinical Development Plan for Sacituzumab Govitecan

Immunomedics, a clinical-stage biopharmaceutical company developing antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases, has received a new patent (U.S....

Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer

Sacituzumab govitecan, also known as IMMU-132, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients...

Immunomedics Receives U.S. patent for Labetuzumab Govitecan

Earlier this week Immunomedics announced the issuance of U.S. patent no. 9,226,973 for additional claims. Under the patent family “Dosages of immunoconjugates of antibodies and...
Photo: San Deigo Bay from Harbor Drive, San Diego, CA, USA. Photo Courtesy: This photo has been released into the public domain by its author, Jon Sullivan. This applies worldwide.

Sacituzumab govitecan Produces Durable Responses in Patients with Advanced Solid Cancers

Sacituzumab govitecan, Immunomedics' lead investigational antibody-drug conjugate or ADC, produced durable responses that exceeded one year in some patients with metastatic triple-negative breast (TNBC),...

Sacituzumab govitecan (IMMU-132) Shows Positive Interim Phase II Results

Sacituzumab govitecan also known as IMMU-132, an antibody-drug conjugate being developed by Immunomedics, a clinical-stage biopharmaceutical company, continues to produce durable responses in patients with...

Patent Extension Protects Immunomedics’ ADC program

Immunomedics, Inc. a clinical-stage biopharmaceutical company based in Morris Plains, NJ (USA) has received U.S. Patent No. 9,107,960 for a new patent family for "Antibody-SN-38 Immunoconjugates...

SAR3419 Achieved Objective Responses Well Above Study Threshold and was Found...

A novel anticancer therapeutic called coltuximab ravtansine (CoR; SAR3419; Sanofi) shows favorable results in the Phase II STARLYTE trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a humanized CD19 mAb linked to DM4, a maytansine analog, developed by ImmunoGen.